

Australian Clinical Labs Limited

ABN 62 006 823 089 Registered Office: 1868-1892 Dandenong Road Clayton VIC 3168 Australia

clinicallabs.com.au

Wednesday, 19 May 2021

TOP 20 SHAREHOLDERS and SHAREHOLDER RANGE

Australian Clinical Labs Limited (ASX: ACL) (**ACL** or **Company**) advises that its top 20 shareholders and investor range is in accordance with the attached documents from its share registry, Link Market Services:

- Top 20 shareholder report as at 19 May 2021; and
- Investor ranges report as at 19 May 2021.

- ENDS -

This announcement was authorised for release to ASX by Eleanor Padman, Company Secretary. For further information regarding this announcement, please contact:

Investors
Eleanor Padman
Company Secretary

Email: Eleanor.Padman@clinicallabs.com.au

Phone: +61 422 002 918

Media

Joe Geran

National Marketing Director

Email: Joe.Geran@clinicallabs.com.au

Phone: +61 499 900 967

About Australian Clinical Labs

ACL is a leading Australian private provider of pathology services. Our 86 NATA accredited laboratories perform over 8 million episodes each year for a range of clients including doctors, specialists, patients, hospitals and corporate clients. ACL is one of the largest private hospital pathology businesses nationally. ACL is focused on its mission of combining talented people, and medical and scientific leadership, with innovative thinking and technologies to empower decision making that saves and improves patients' lives.



PAGE NUMBER: REPORT DATE : 19/05/2021

REPORT TIME : 07.30.03

AUSTRALIAN CLINICAL LABS LIMITED

FIRST 20 INVESTORS REPORT WEDNESDAY 19 MAY 2021

Rank ——	Investor	Current Balance	% Issued Capital			
Sec. Group: ORD - FPO & ESC						
1	CRESCENT CAPITAL PARTNERS V LP.	40,385,443	20.01%			
2	NATIONAL NOMINEES LIMITED	19,067,704	9.45%			
3	HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED	16,813,197	8.33%			
4	INSTANZ NOMINEES PTY LTD <the a="" c="" hearts="" trust=""></the>	14,036,045	6.95%			
5	CITICORP NOMINEES PTY LIMITED	13,442,963	6.66%			
6	CCP TRUSCO 1 PTY LTD <crescent a="" c="" capital="" partners="" specific="" trust="" va=""></crescent>	12,383,350	6.14%			
7	CCP TRUSCO 5 PTY LTD <crescent a="" c="" designated="" partners="" trust="" vb=""></crescent>	6,207,125	3.08%			
8	BNP PARIBAS NOMS PTY LTD <drp></drp>	5,606,748	2.78%			
9	CCP TRUSCO 4 PTY LTD <crescent a="" c="" designated="" partners="" trust="" va=""></crescent>	5,533,472	2.74%			
10	CCP TRUSCO 2 PTY LTD <crescent a="" c="" capital="" partners="" specific="" trust="" vb=""></crescent>	5,426,246	2.69%			
11	MORGAN STANLEY AUSTRALIA SECURITIES (NOMINEE) PTY LIMITED <no 1="" account=""></no>	4,922,814	2.44%			
12	J P MORGAN NOMINEES AUSTRALIA PTY LIMITED	4,922,535	2.44%			



PAGE NUMBER : 2 REPORT DATE : 19/05/2021 REPORT TIME : 07.30.03

AUSTRALIAN CLINICAL LABS LIMITED

FIRST 20 INVESTORS REPORT WEDNESDAY 19 MAY 2021

Rank	Investor	Current Balance	% Issued Capital
13	CS THIRD NOMINEES PTY LIMITED < HSBC CUST NOM AU LTD 13 A/C>	3,814,823	1.89%
14	MERRILL LYNCH (AUSTRALIA) NOMINEES PTY LIMITED	3,750,000	1.86%
15	UBS NOMINEES PTY LTD	3,314,043	1.64%
16	PERPETUAL CORPORATE TRUST LTD <roc asia="" atf="" capital="" co-inves="" fund="" ii="" limited="" pac="" pty="" roc=""></roc>	3,074,742	1.52%
17	BRISPOT NOMINEES PTY LTD < HOUSE HEAD NOMINEE A/C>	2,996,475	1.48%
18	PERPETUAL CORPORATE TRUST LTD <roc act="" atf="" capital="" equity="" fund="" limited="" no.3="" private="" pty=""></roc>	2,635,495	1.31%
19	MERRILL LYNCH (AUSTRALIA) NOMINEES PTY LIMITED	2,250,000	1.11%
20	MELINDA MCGRATH	2,123,508	1.05%
	TOTAL FOR TOP 20:	Inve 172,706,728	estors 20 85.57%

	Investors		
TOTAL IN THIS REPORT:	172,706,728	20	85.57%
TOTAL OTHER INVESTORS:	29,127,287	2,259	14.43%
GRAND TOTAL:	201,834,015	2,279	100.00%

end of report



PAGE NUMBER : 1 REPORT DATE : 19/05/2021 REPORT TIME : 07.26.11

AUSTRALIAN CLINICAL LABS LIMITED

INVESTOR RANGES WEDNESDAY 19 MAY 2021

Ranges Investors Securities % Issued Capital

Security Group: ORD FPO & ESC

Totals for Security Group ORD

1 to 1000	806	258,059	.13
1001 to 5000	759	2,518,771	1.25
5001 to 10000	381	2,955,413	1.46
10001 to 100000	280	5,944,476	2.95
100001 and Over	53	190,157,296	94.22
Total	2,279	201,834,015	100.00

end of report